We recently presented a poster at the ASN Kidney Week in Texas, showcasing the kidney-targeted delivery of siRNA using our RIBO-PepSTAR™ peptide conjugates. This work highlights the growing validation of Ribos Renal platform – designed to silence the right target in the right cell type, specifically in the kidney.
By enabling precise delivery of small interfering RNAs to the kidney, we aim to unlock new possibilities for treating chronic kidney disease (CKD) and improving patient outcomes.
Our preclinical data demonstrated proximal tubular specific uptake cross-species from rodents to NHPs with a knock-down efficiency of up to 80%. Also, physiological Proof of Concept has been shown in a rodent model of type 2 diabetes, demonstrating profound kidney specific knock-down of the target gene involved.
We are excited about the discussion this sparked and the momentum toward more targeted, effective therapies for this group of patients.
Link to abstract: Journal of the American Society of Nephrology
